Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 1.00 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.54 |
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15544537 | 0.81 | CNR2 (0.68) | CNR2HSD11B1XIAPBIRC2NOTUM | |
| SCHEMBL15546212 | 0.78 | CNR2 (0.72) | CNR2HSD11B1SMN1; SMN2 | |
| SCHEMBL15544380 | 0.78 | CNR2 (1.00) | CNR2HSD11B1NOTUM | |
| SCHEMBL2530222 | 0.77 | CNR2 (0.62) | CNR2XIAPBIRC2NOTUMHTR2A | |
| SCHEMBL15545085 | 0.77 | CNR2 (0.63) | CNR2HSD11B1SMN1; SMN2 | |
| SCHEMBL15587311 | 0.77 | CNR2 (0.61) | CNR2XIAPBIRC2NOTUMHTR2A | |
| SCHEMBL16600192 | 0.76 | CNR2 (0.61) | CNR2XIAPBIRC2NOTUMHTR2A | |
| SCHEMBL30038606 | 0.76 | NOTUM (0.78) | CNR2XIAPBIRC2NOTUMHTR2A | |
| SCHEMBL15546058 | 0.76 | CNR2 (1.00) | CNR2HSD11B1NOTUMSMN1; SMN2 | |
| SCHEMBL16661711 | 0.76 | CNR2 (0.61) | CNR2HSD11B1XIAPBIRC2NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2870139-B1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2016-06-15 | — | — | EP | claimed |
| US-9090615-B2 | Adamantyl derivatives as cannabinoid receptor 2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | claimed |
| US-20150111886-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2015-04-23 | — | — | US | claimed |
| EP-2870139-B1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN LA ROCHE (CH) | 2016-06-15 | — | — | EP | disclosed |
| US-9090615-B2 | Adamantyl derivatives as cannabinoid receptor 2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090615-B2 | Adamantyl derivatives as cannabinoid receptor 2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090615-B2 | Adamantyl derivatives as cannabinoid receptor 2 agonists | HOFFMANN-LA ROCHE INC. (US) | 2015-07-28 | — | — | US | disclosed |
| EP-2870139-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2015-05-13 | — | — | EP | disclosed |
| US-20150111886-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150111886-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-20150111886-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | HOFFMANN-LA ROCHE INC. (US) | 2015-04-23 | — | — | US | disclosed |
| WO-2014005968-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111886-A1 | NOVEL ADAMANTYL DERIVATIVES AS CANNABINOID RECEPTOR 2 AGONISTS | CNR1, CNR2, GPR18 | CNR2 2/4885HSD11B1 1447/4885XIAP 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.